Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SEROTONIN IN ACTION

Financiado

Cerrado

Serotonergic modulation of cortical activity in vivo from neurons to networks a...

Serotonergic modulation of cortical activity in vivo from neurons to networks and implications for autism spectrum disorders Anti-depressant drugs such as fluoxetine (Prozac) increase levels of serotonin (5HT) in the brain, but little is known about how they affect the function of the nervous system. 5HT is implicated in a wide spectrum of brain functio... ver más

31/05/2016

UEDIN

222K€

Presupuesto del proyecto: 222K€

Líder del proyecto

THE UNIVERSITY OF EDINBURGH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-05-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UEDIN

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FLEX5 Establishing the dual role of serotonergic neurons of the do... 171K€ Cerrado

5HT-OPTOGENETICS Optogenetic Analysis of Serotonin Function in the Mammalian... 2M€ Cerrado

PRESERT PRESERT: linking prefrontal cortex, serotonin transporter an... 173K€ Cerrado

SAF2012-35183 PAPEL DE LA CORTEZA INFRALIMBICA EN DEPRESION: CONECTIVIDAD... 351K€ Cerrado

SEROTONIN and BEYOND Serotonin and BEYOND Brain development research Excelling Y... 4M€ Cerrado

SAF2014-56877-R ESTUDIO DE LOS MECANISMOS TRANSCRIPCIONALES QUE REGULAN LA D... 242K€ Cerrado

Líder del proyecto

THE UNIVERSITY OF EDINBURGH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 222K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Anti-depressant drugs such as fluoxetine (Prozac) increase levels of serotonin (5HT) in the brain, but little is known about how they affect the function of the nervous system. 5HT is implicated in a wide spectrum of brain functions and disorders. However, its precise role remains controversial and enigmatic. This is partly due to the previous inability to adequately isolate 5HT action in vivo. Recent developments in genetic tools and imaging techniques now offer an unprecedented opportunity to investigate such mechanisms in the living brain. This project aims to isolate 5HT transmission in the cerebral cortex and determine the precise cellular mechanisms underlying serotonergic neuromodulation of brain activity. Our objectives are to determine the action of 5HT in awake-behaving animals in three main ways: (1) on specific neuronal populations, at the network and single-cell level, by the local application of 5HT modulators (including fluoxetine); (2) when endogenously released, by controlling 5HT neuronal activity with optogenetic tools; and (3) on pathologic cortical network activity in an animal model of autism spectrum disorders. We will use the primary visual cortex as a model cortical area, investigating the role of 5HT in visually-evoked and activity-dependent cortical activation under normal conditions and during network dysfunction in autism spectrum disorders. In this project we will use state of the art in vivo two-photon calcium imaging and advanced genetic tools, including optogenetics. These cutting edge techniques will allow us to precisely activate 5HT neurons and measure the resulting effects on neuronal populations with single-cell resolution. The results will apply beyond the visual system to more broadly inform on cellular mechanisms of 5HT action in the central nervous system and its dysfunction in neurological disorders, leading to future advancements for therapeutic targeting.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores